Introduction {#sec1-1}
============

Cochlear implant (CI) is a medical device designed to restore hearing perception in patients with severe to profound hearing impairment who fail to benefit adequately from hearing aids ^[@ref1]^. Many studies agree that providing CI early in cases of congenital hearing loss helps patients to develop auditory skills that are comparable with those of their normally-hearing peers ^[@ref2],[@ref3]^. Reported outcomes may differ according to the different aetiologies and degrees of hearing loss, prompting changes in neural organisation secondary to auditory deprivation ^[@ref4],[@ref5]^. It is well known that there is a sensitive period (before 3.5 years of age) for inserting the CI in order to achieve normal central auditory development and improve language skills ^[@ref6]^, whereas subjects fitted with CI after this period have worse outcomes ^[@ref9]^.

The problem of sensory restoration in early deafness is well explained in a review by Kral et al. ^[@ref10]^ on the basis of the connectome concept. The authors said that sensory loss can be seen as a disease involving the connectome, which is a synaptic network whose development depends on sensory experience.

The proper functioning of auditory processing needs integration of many types of information: neuronal activity relies on both bottom-up and top-down integration ^[@ref11]^. Hearing loss causes changes in connectivity "within the auditory system, between sensory systems, and between the auditory system and centres serving higher-order neurocognitive functions" ^[@ref10]^. Auditory input presumably activates a cortical network of higher-order functions, and sensory restoration with CI can improve the connectivity in this network ^[@ref10]^. This system can be studied using neurophysiological and neuroimaging techniques.

Functional MRI (fMRI) is a powerful neuroimaging method for assessing spatial activations, but is only partially feasible in patients with CI due to factors that include a sizable artefact and the risk of the device being displaced due to potential movement within a magnetic field greater than 1.5 Tesla ^[@ref12],[@ref13]^. Other approaches have been used to identify cortical auditory activation in patients fitted with CI, such as NIRS or PET. These procedures, however, have good spatial but poor temporal resolution.

Electroencephalography (EEG), on the other hand, allows estimation of cortical areas of activation even at sub-second timescales. Despite poor spatial resolution, EEG has an excellent time resolution. It is completely non-invasive, easy to use, inexpensive and perfectly compatible with cochlear implantation.

In particular, the event-related potential (ERP) P300 may be an excellent measure of attention and memory operations ^[@ref14]^. The P300 wave is one of the late auditory event-related potentials, and is an objective measurement of cognitive processes induced by auditory stimulation. It reflects the cortical processes involved in stimulus evaluation and categorisation, memory operations and decision-making skills. Very few studies have investigated P300 in prelingually deaf CI recipients. Jordan et al. ^[@ref15]^ measured P300 in a very small population of three prelingually and two postlingually deaf CI recipients. Henkin et al. ^[@ref16]^ enrolled 10 prelingually deaf children fitted with CI (9 to 14 years old) and investigated how an increase of acoustic--phonetic difficulty affected the P300 potential. The interaction between task difficulty and prelingual deafness could not be investigated, however, because there was no control group. Reis et al. ^[@ref17]^ studied P300 latency and amplitude in 29 patients with prelingual, severe-to-profound sensorineural hearing loss (without CI), and found significant differences in latency and amplitude that were related to age and severity of hearing loss, respectively. The study had no control group and the ERP was only delivered in Cz electrode. Beynon et al. ^[@ref18]^ examined 10 congenitally deaf children fitted with CI when 5 or more years old, who had been using the device for at least 2 years. This study included a control group of normal-hearing subjects with longer P300 latencies (mean 500 msec) than those reported in the literature (mean 300 msec) ^[@ref19]^. A previous study ^[@ref20]^ compared N100, N200 and P300 latencies in 15 prelingually deaf CI recipients with those of nine normal-hearing controls. We found all latencies were significantly longer in the patient group than in controls (whose values were consistent with the literature).

Henkin et al. ^[@ref21]^ studied the P3 component elicited by non-speech and speech oddball discrimination tasks in four prelingual patients with CI. They used LORETA (Low-Resolution Electromagnetic Tomography) ^[@ref22]^, a noninvasive functional neuroimaging method based on scalp-recorded EEG, to estimate cortical sources of EEG activity. They found differences between patients and controls, and also between right and left CI recipients.

To date, the age at implant, its period of use and their interaction have not been fully investigated. The aim of our study was to investigate these issues: this was done through assessment of the cortical sources of P300, using LORETA software, in prelingually deaf CI recipients compared with age-matched normal-hearing controls.

Materials and methods {#sec1-2}
=====================

Inclusion criteria {#sec2-1}
------------------

The inclusion criteria for the study group were: a) congenital non-progressive severe-to-profound bilateral sensorineural hearing loss; b) use of CI; c) no associated disabilities or diseases.

Patients {#sec2-2}
--------

We enrolled 20 subjects in the control group (3 males and 17 females) and 20 subjects (attending the ENT Clinic at Padua University Hospital) in the study group (11 males and 9 females). The mean age of the control group was 29.05 ± 16.4 (range:10.1-58.4), while for the patient group it was 31.10 ± 18.4 (range:10.5-62.4). The age difference was not statistically significant (p = 0.3).

Age at the time of first fitting CI (CI Age) and period of CI use are considered very important parameters. Patients were then divided into groups according to the age at time of CI first fitting, before or after the age of 3 years, (hereinafter referred to as early or late CI age, respectively), and according to the duration of CI use at the time of ERPs recording, less or more than 1 year, (hereinafter named as long or short CI use, respectively).

The three groups are therefore identified as follows: 1) group A, 8 early CI age and long CI use subjects; 2) group B, 5 late CI age and long CI use subjects; 3) group C, 7 late CI age and short CI use subjects. No early CI age and short CI use patients were included in the study because they were too young to perform the task required. The characteristics of the patient groups (sex, age at time of the test, aetiology of hearing loss, age at time of first CI fitting, side of CI, CI brand and study subgroup) are summarised in [Table I](#table001){ref-type="table"}. Each patient group was compared with a control group matched for mean age and sample size. Controls were normal hearing subjects (thresholds lower than 30 dB at all frequencies). The characteristics of the three groups (age for both control and patient groups, plus age at time of CI and duration of CI use for the patient groups) are summarised in [Table II](#table002){ref-type="table"}.

The auditory benefit of the CI was assessed in terms of the free-field aided threshold by measuring the pure-tone average (PTA), which is expressed in decibels of hearing level (dB HL) and corresponds to the average air-tonal threshold at the frequencies of 500, 1000 and 2000 Hz. The mean PTA was 32.76 dB HL (range 25-41.2 dB HL) for group A, 33.75 dB HL (range 22.5-41.25 dB HL) for group B, and 45.17 dB HL (range 31.25-61.25 dB HL) for group C.

P300 recording {#sec2-3}
--------------

EEG recordings were obtained with 19 electrodes positioned according to the International 10--20 System (Fp1, F3, C3, P3, O1, F7, T3, T5, Fz, Cz, Pz, Fp2, F4, C4, P4, O2, F8, T4 and T6) with a linked ears reference. The sampling rate was 2048 Hz. A time window of 700 ms was considered (70 ms pre- and 630 ms post-stimulus). An amplitude window (±70 μV) was used for artifact rejection.

The impedance measured for each electrode was lower than 5 kOhm.

The active oddball paradigm was used. It consisted of a sequence of target and standard stimuli (1/7 proportion, 60 target stimuli), randomly presented to the subjects. The stimuli were audio tones on different frequencies, with a comfortable intensity level for all patients (1000 Hz for the standard, and 2000 Hz for the target; duration 100 msec for both; ISI = 1020-1100; intensity = 90 dB). All subjects were asked to take count of the number of target stimuli administered.

LORETA is a Laplacian-weighted minimum norm algorithm belonging to a family of linear inverse solution procedures ^[@ref23]^. It is used to estimate cortical sources of scalp potentials ^[@ref21],[@ref24]^. Estimated electrical sources are obtained considering a brain model based on the Talairach probability brain atlas, digitised at the Brain Imaging Center of the Montreal Neurological Institute ^[@ref25]^. The model includes 6239 voxels (5x5x5 mm resolution). Notably, LORETA is a reference-free method of EEG analysis.

Types of analysis {#sec2-4}
-----------------

We performed two analyses: a simple study of N200 and P300 latencies and a LORETA cortical source analysis, including a linear regression analysis with duration of CI use and age of CI surgery as covariates.

Latency analysis {#sec2-5}
----------------

As in the literature and clinical practice, according to which Cz provides the best evoked response, we always considered Cz for this analysis. P300 latencies were identified at the maximum wave amplitude of the third positive peak point. The identification of P300 peak latency was performed through visual assessment of the target stimuli traces ^[@ref26]^. In any case, the maximum positive deflection designated as P300 was calculated automatically by the software for P300 acquisition, thus allowing for validation of the latency values determined by visual analysis of the traces.

Cortical source analysis {#sec2-6}
------------------------

First, the difference between the averaged rare response and the frequent averaged response was calculated for the 19 channels, and for each patient.

This new function ("rare stimuli response minus frequent stimuli response", which may be considered as the pure target stimuli effect) was collapsed into 63 bins, each resulting from the averaged values of 10 msec. LORETA was then applied to this new function considering two time ranges: one from 180 msec to 270 msec (the common range of N200 elicitation for all groups), the other from 270 msec to 460 msec (the common range of P300 elicitation for all groups). The difference in cortical estimated activation were performed comparing the pure target stimuli effect between patients and controls in the three previously-described groups.

Statistical analysis {#sec2-7}
--------------------

Normality of data was checked using the Kolmogorov Smirnov test. The t-test for independent groups was used for comparing latencies in the group as a whole (patients and controls).

The statistic used in LORETA analysis was a Student's t-test on log-normalised data. Correction for multiple comparisons was performed using the randomisation approach ^[@ref27]^ with 5000 randomisations.

The significance level was set at p \< 0.05. Latencies analysis were performed using the Statistica 12.0 software package, while source analysis including regression analysis were performed using the LORETA software package.

Ethical issues {#sec2-8}
--------------

The local institutional ethics committee approved the study (n. 3842AO16). All experiments were conducted with the informed and overt consent of each participant or caregiver, in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and the standards established by the local Institutional Review Board.

Results {#sec1-3}
=======

All subjects (patients and controls) correctly identified all the target stimuli.

Latency analysis {#sec2-9}
----------------

Comparing patients and controls in the study population as a whole, the N100, N200 and P300 latencies were significantly longer in patients than in controls (128.8 ± 19 msec and 97.2 ± 16, respectively, for N100, p = 0.003; 239.6 ± 28 msec and 201.5 ± 20, respectively, for N200, p = 0.0001; 353.1 ± 47 and 299.5 ± 21, respectively, for P300, p = 0.0002).

The N200-N100 interval did not differ significantly in patients and in controls (107.3 ± 31.6 msec and 103.7 ± 19.9, respectively; p = 0.6) ([Fig 1](#fig001){ref-type="fig"}).

Cortical source analysis {#sec2-10}
------------------------

This analysis was performed as explained in the Methods. In group A ([Fig. 2](#fig002){ref-type="fig"}), no significant difference was found between patients and controls in the cortical areas, either for N200 (180-270 ms time window) or for P300 (270-460 time window). In group B ([Fig. 3](#fig003){ref-type="fig"}), there was greater activation in frontal areas for both N200 and P300 wave in controls, but the difference was not significant, whereas in group C ([Fig. 4](#fig004){ref-type="fig"}) this difference reached statistical significance (p \< 0.05). More precisely, in the N200 time window, controls exhibited a higher activation in frontal areas (BA 8,9 and10) and in the cingulate cortex (BA 24, 32 and 33); and in the P300 time window, we found a significantly higher activation again in frontal areas (BA 10,11, and 25) and in cingulate cortex (BA 32). In the patient group, the amount of cortical activation was found to be significantly directly correlated with duration of implant use and significantly correlated inversely with age at implant, for both N200 and P300 waves, as shown in [Table III](#table003){ref-type="table"}.

Discussion {#sec1-4}
==========

The latency analysis showed a significant increase in the N100, N200 and P300 peaks in patients compared to controls ([Fig. 1](#fig001){ref-type="fig"}), while the P300-N100 and the N200-N100 inter-peak latencies did not differ significantly between patients and controls. This means that the difference in N200 and P300 latencies found between patients and controls is due mainly to the N100 latency lag (of about 25-30 msec) in the patient group, a finding previously reported by Ghiselli et al. ^[@ref20]^. Using LORETA on magnetoencephalographic data, Larson ^[@ref28]^ found that the cortical generators of N100, elicited by the oddball paradigm, were located in the Heschl's gyrus, where previous studies identified the tonotopic map of the human auditory cortex (for an exhaustive review, see Saenz ^[@ref29]^). There can be no this tonotopic cortical map without the auditory sensory modality, and thus a prelingually deaf patient needs to "create" a new cortical network to analyse acoustic input. Furthermore, the absence of auditory experience compromises both the primary field and more extensively the higher-order areas ^[@ref30]^. It may be that such a network cannot achieve the same performance as a perfect tonotopic cortex.

From a point of view of cortical activation, LORETA analysis disclosed a very clear difference when comparing a group of patients (group C) who had only been using CI for a very short period of time (less than one year) and had suffered long-term neural deprivation, with an age-matched control group. A statistically higher amount of activation in the frontal areas and cingulate cortex was apparent in the controls in comparison with patients, for both the N200 and the P300 waves. Conversely, when comparing an early-implanted patient group that had had long-term CI use (group A) with an age-matched control group, no significant differences emerged between patients and controls for either N200 or P300 ([Fig. 2](#fig002){ref-type="fig"}). It is well known that long-term implant use and early CI fitting are associated with good audiological performance ^[@ref6]^, but it is noteworthy that these features seem to be associated with a normalisation from neurophysiological standpoint also.

These findings depict two extreme conditions: late implant and short time of CI use, versus early implant and long CI use. An intermediate condition is represented by the patient belonging to group B, which had been using CI for more than one year. In this case a slight, but not statistically significant, tendency for higher activation in controls than in patients was found ([Fig. 3](#fig003){ref-type="fig"}).

These results were congruous with the LORETA monovariate regression analysis performed in the patient group, with age of implant and duration of CI use as covariates: the amount of cortical activation was significantly correlated with duration of implant use and significantly correlated inversely with age at implant, for both N200 and P300 waves. It is very important to stress that our results do not imply cognitive impairment due to prelingual deafness: CI provides a new sensory modality in this type of patients, and their neuronal plasticity restores -- or rather creates -- a functional network which involves the areas implicated in sensory and cognitive modalities. Thus, in other words, CI gives these cortical areas access to a new (for deaf patients) sensory modality. The duration of CI use is clearly crucial: our data suggest that even in case of late-implant, prolonged CI use restores the auditory network. Unfortunately, LORETA software cannot perform multivariate regression analysis, so the pure effect of the duration of CI use and age of implant could not be determined.

The main limitations of the present study are: (i) small sample size; (ii) lack of a group of early-implanted patients with a short period of CI use; (iii) unfeasibility of a cortical source analysis of the N100 wave and limited number of channels. With regards to (i), further patient recruitment is in progress to increase the size of groups A and B to better investigate the relationship between CI age and CI period of use needed for a good performance. The chance to study early-implanted patients with a short use of their CI coincides with the feasibility of administering a P300 paradigm to very young children. The number of EEG channels ^[@ref20]^ does not allow for high spatial resolution. However, our results showed strong significance with regards to our specific question. Therefore, various examples of the use of 19 channels in the ERPs cortical source analysis are available in the scientific literature ^[@ref31]^.

Figures and tables {#sec1-5}
==================

![Grand average of target stimuli recorded in Cz in controls (black line) and patients (grey lines, from darker to lighter) in groups A, B and C.](aoi-2020-01-64-g001){#fig001}

![LORETA probabilistic map in cortical difference of activation between patients and controls, in group A. Red colours represent a greater activation in control group, more evident from dark red to yellow. On the contrary, blue colours represent greater activation in the patient group, more evident from dark to light. No significant difference in activation was found in either N200 (above) or in P300 (bottom).](aoi-2020-01-64-g002){#fig002}

![LORETA probabilistic map in cortical difference of activation between patients and controls, in group B. Red colours represent a greater activation in control group, more evident from dark red to yellow. On the contrary, blue colours represent greater activation in the patient group, more evident from dark to light. A greater activation was found in controls, but this difference was not statistically significant in either N200 (above) or in P300 (bottom).](aoi-2020-01-64-g003){#fig003}

![LORETA probabilistic map in cortical difference of activation between patients and controls, in group C. Red colours represent a greater activation in control group, more evident from dark red to yellow. On the contrary, blue colours represent greater activation in the patient group, more evident from dark to light. A greater activation in control group was found (yellow) in the frontal areas and cingulate cortex: this difference was statistically significant in both N200 (above) and P300 (bottom).](aoi-2020-01-64-g004){#fig004}

###### 

Clinical characteristics of the patient group. CX26 = connexin 26.

  ---------------------------------------------------------------------------------------------------------------------------------
  Sex   Age at time of test\   Etiology   Age at first time of CI fitting (years)   Side of CI   CI Brand           Patient group
        (years)                                                                                                     
  ----- ---------------------- ---------- ----------------------------------------- ------------ ------------------ ---------------
  F     16.51                  Unknown    1.51                                      L            Cochlear^®^        A

  F     14.82                  CX26       1.55                                      R            Advanced Bionics   A

  F     13.29                  CX26       2.60                                      R            Advanced Bionics   A

  M     11.30                  Unknown    2.53                                      R            Cochlear^®^        A

  M     12.41                  CX26       1.63                                      R            Advanced Bionics   A

  M     10.59                  CX26       2.27                                      L            Cochlear^®^        A

  M     10.50                  Unknown    3.02                                      R            Cochlear^®^        A

  F     20.00                  CX26       2.45                                      L            Medel              A

  M     58.70                  Unknown    57.36                                     L            Advanced Bionics   B

  F     25.83                  Unknown    22.52                                     L            Cochlear^®^        B

  M     41.99                  Rubella    39.86                                     R            Advanced Bionics   B

  M     47.32                  Unknown    42.96                                     BIL          Advanced Bionics   B

  F     21.50                  CX26       16.77                                     R            Cochlear^®^        B

  M     39.20                  Rubella    38.85                                     R            Advanced Bionics   C

  M     17.92                  CX26       17.21                                     L            Advanced Bionics   C

  F     42.38                  Unknown    41.31                                     L            Advanced Bionics   C

  M     57.69                  Unknown    57.36                                     L            Advanced Bionics   C

  F     62.41                  Unknown    61,87                                     R            Cochlear^®^        C

  M     46.92                  Rubella    46.73                                     L            Medel              C

  F     50.80                  Familial   50.61                                     R            Advanced Bionics   C
  ---------------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of the three groups (patients and age-matched controls). Ages (in years) are expressed as mean ± SD and range. CI Age means the age at first time of CI fitting (in years).

  ------------------------------------------------------------------
  Clinical   Patients         Controls         T test (p value)   
  ---------- ---------------- ---------------- ------------------ --
  A          N                8                8                  

  Age        13.68 ± 3.30\    13.83 ± 4.77\    0.82               
             (10.50-20.00)    (10.08-23.41)                       

  CI Age     2.20 ± 0.56\                                         
             (1.51-3.02)                                          

  CI use     11.48 ± 3.52\                                        
             (7.48-17.55)                                         

  B          N                5                5                  

  Age        39.07 ± 15.38\   39.08 ± 13.64\   0.98               
             21.50-58.70      (22.48-58.39)                       

  CI Age     35.89 ± 16.36\                                       
             (16.8-42.9)                                          

  CI use     3.17 ± 1.44\                                         
             (1.33-4.73)                                          

  C          N                7                7                  

  Age        45.33 ± 14.58\   39.27 ± 13.61\   0.47               
             (17.92-62.41)    (17.69-58.39)                       

  CI Age     42.01 ± 13.83\                                       
             (17.21-57.36)                                        

  CI use     0.47 ± 0.35\                                         
             (0.2-1)                                              
  ------------------------------------------------------------------

###### 

Linear correlation coefficient (r) and corresponding significance between amount of cortical activation and, respectively, duration of CI use and age at first time of CI fitting.

                                    N200                    P300
  --------------------------------- ----------------------- -----------------------
  Duration of CI use                r = 0.78 (p \< 0.01)    r = 0.76 (p \< 0.01)
  Age at first time of CI fitting   r = -0.71 (p \< 0.01)   r = -0.68 (p \< 0.01)
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